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Stefano Cascinu, MD, PhD,|||||| and Nicola Silvestris, MD*†††Objectives: Two issueswere put forth by clinicians in the management of
the advanced stages of rare variants of pancreatic ductal adenocarcinoma
and other exocrine histotypes with peculiar clinical and pathological fea-
tures: Do chemotherapy regimens recommended in pancreatic ductal ade-
nocarcinoma patients have a clinical activity in rare pancreatic tumors?
Or should other chemotherapy combinations be considered in this subset
of patients?
Methods: We conducted a multicenter retrospective study that collected
data from 2005 to 2016 at 14 Italian cancer centers with the aim to evaluate
tumor response and time to progression for first- and second-line and
overall survival.
Results: Of approximately 4300 exocrine pancreatic cancer patients, 79
advanced cases affected by rare histological types were identified, with
pancreatic acinar cell cancer (n = 23), pancreatic adenosquamous cancer
(n = 16), andmucinous cystic neoplasmwith an associated invasive mucin-
ous cystadenocarcinoma (n = 15) most represented. Survival analyses for
each subgroup in relation with the different chemotherapy regimens
showed the lack of statistical significance correlations.
Conclusions: Because of the lack of clinical trials in patients affected by
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P ancreatic ductal adenocarcinoma (PDAC) represents approxi-mately 85% of all pancreatic malignancies.1 According to
the World Health Organization classification, the remaining rare
pancreatic histotypes are represented by variants of PDAC, very
rare carcinomas of probable ductal differentiation, and other exo-
crine variants.2 Among these rare malignancies, those with a higher
incidence are pancreatic adenosquamous carcinoma (PASC) (1%–
4%),3 pancreatic acinar cell carcinoma (PACC) (<2%),4 cystic tumors
(approximately 10%, with very low incidence of malignant cases),5
and pancreatic undifferentiated and osteoclast-like carcinoma
(<1%).6 Pancreatic carcinosarcoma is considered as a separate en-
tity because of its exceedingly rare occurrence and its character-
ized dual epithelial and mesenchymal histological feature.7
More than half of these patients show advanced disease at the
onset, whereas most of them (57%–100%) relapse after curative
surgery.8 Because of the low incidence of these malignancies,
their main clinical features are reported only in case series or in
retrospective observational analyses. Furthermore, patients af-
fected by these rare pancreatic tumors are excluded from clinical
trials that evaluate systemic treatments. The following 2 issues
were put forth by clinicians in the management of the advanced
stages of these patients: Do chemotherapy regimens recom-
mended in PDAC patients have a clinical activity in rare pancre-
atic tumors? Or should other chemotherapy combinations be
considered in this subset of patients? These questions prompted
this multicentric retrospective study that evaluated the activity
and the efficacy of different chemotherapy regimens used over
time in patients with advanced pancreatic tumors. We also re-
viewed the current literature on these histological variants, focus-
ing our attention on systemic treatments.MATERIALS AND METHODS
This retrospective, noninterventional study collected data
from 2005 to 2016 of all patients observed at 14 Italian cancer
centers who were affected by one the following rare histological
types of advanced pancreatic cancer, diagnosed according to
World Health Organization criteria: PASC, pancreatic squamous
cell carcinoma (PSCC), signet ring cell carcinoma of the pancreas
(SRCCP), undifferentiated (anaplastic) carcinoma, osteoclast-likewww.pancreasjournal.com 1
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TABLE 1. Demographics of Patients With Rare Exocrine
Histotypes (n = 79)
Patients Characteristics Frequency (%) or Median (IQR)
Age, y 65.2 (57.9–70.6)
Histotype
PACC 23 (29.1)
PASC 16 (20.2)
Carcinosarcoma 5 (6.3)
Medullary carcinoma 1 (1.3)
Osteoclast-like carcinoma 2 (2.5)
Pancreatoblastoma 1 (1.3)
PSPPC 4 (5.1)
Undifferentiated carcinoma 3 (3.8)
Clear cell carcinoma 2 (2.5)
PSCC 3 (3.8)
SRCCP 4 (5.1)
MPCAC 15 (18.9)
T
1 1 (1.3)
2 16 (20.2)
3 44 (55.7)
4 13 (16.5)
Unavailable 5 (6.3)
Primary tumor location
Head 61 (77.2)
Body 8 (10.1)
Tail 10 (12.7)
N
0 21 (26.6)
1 40 (50.6)
Unavailable 18 (22.8)
M
0 40 (50.6)
1 39 (49.4)
Stage at diagnosis
I/II 25 (31.6)
III 13 (16.5)
IV 41 (51.9)
First line
Yes 79 (100)
Second line
Yes 41 (51.9)
PSPPC indicates pancreatic solid paseudopapillary carcinoma.
FIGURE 1. Kaplan-Meier curves of OS and TTP-1 according to 3
principal groups of diagnosis. Survival analysis reveals that patients
with a diagnosis of PASC have a significantly worse OS (A) and TTP-1
(B) compared with patients with other diagnosis (log-rank P < 0.05).
Editor’snote:Acolor imageaccompanies the online versionof this article.
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                  giant cell carcinoma, mucinous cystic neoplasm with an associated
invasive mucinous cystadenocarcinoma of the pancreas (MPCAC),
PACC, pancreatoblastoma, pancreatic solid pseudopapillary carci-
noma, and carcinosarcoma. Moreover, clear cell carcinoma and
medullary carcinoma of the pancreas represent very rare variants
of PDAC.
Information regarding patients was reviewed for basic clini-
cal features, chemotherapeutic regimens, and outcomes. Data
were collected by clinical and electronic records of participating
centers and analyzed by the coordinating center (National Cancer
Institute “Giovanni Paolo II,” Bari, Italy).
The baseline characteristics of the patients were described
and reported as frequencies (%) for categorical variables or me-
dian with interquartile range (IQR) for continuous variables.2 www.pancreasjournal.com
                       Copyright © 2018 Wolters Kluwer Health, Inc. Unautho
               This paper can be cited using the date of access and the unTumor responses were evaluated according to the Response Eval-
uation Criteria in Solid Tumor version 1.1.9 Time to tumor pro-
gression (TTP [TTP-1 and TTP-2]) were calculated as the time
between the start of first- and second-line chemotherapy and the
documented tumor progression, respectively. Overall survival
(OS) was calculated from the date of first chemotherapy cycle to
the date of death due to any cause. Survival statistics (TTP-1,
TTP-2, and OS) were estimated using the Kaplan-Meier method
and compared among groups of interest (PASC, PACC, and
MPCAC) using the log-rank test. If patients were alive, they were
censored at the time of last follow-up. Survival analyses for each
subgroup in relationwith the different chemotherapy regimenswere
also performed. Results were expressed asmedianwith correspond-
ing 95% confidence intervals (95%CIs) and graphically reported as
curves or histograms. The statistical significance was achieved at
P < 0.05. All the analyses were performed with the Statistical Anal-
ysis System (version 9.4; SAS Institute, Cary, NC).
This study was approved by the Ethical Committee of the
National Cancer Institute “Giovanni Paolo II,” Bari, Italy, and per-
formed according to the Helsinki Declaration.
RESULTS
After reviewing the records of approximately 4300 exocrine
pancreatic cancer patients, 79 advanced cases affected by the
above rare, histological types were identified. Baseline features© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 2. Kaplan-Meier curves of OS according to all groups of
diagnosis. Survival analysis reveals that patients with a significantly
worseOS are thosewith the followingdiagnosis: PSCC, carcinosarcoma,
andpancreatoblastoma (log-rankP<0.0001).Editor’snote:Acolor
image accompanies the online version of this article.
FIGURE 3. Kaplan-Meier curves of OS in patients with PACC
diagnosis according to FP plus oxaliplatin (A) gemcitabine
(B) treatments. Survival analysis reveals an intriguing trend in OS
despite the lack of statistical significance: patients treated with FP
plus oxaliplatin seem tohave a better survival than the others (A). On
the contrary, patients treated with gemcitabine alone have a
worse survival than the others (B). Editor’s note: A color image
accompanies the online version of this article.
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                 are reported in Table 1.Median agewas 65 years (IQR, 58–70 years).
The most frequent histotypes were PACC (n = 23 [29.1%]), PASC
(n = 16 [20.2%]), and MPCAC (n = 15 [18.9%]). Fifty-four pa-
tients (68.3%) presented an advanced stage at diagnosis, with
most of the tumors localized at the head of the pancreas. The
remaining patients developed metastases after surgery, which
were followed, in some cases, by adjuvant treatments. Thirteen
different chemotherapy schedules, mostly gemcitabine based,
and 16, mostly fluoropyrimidine (FP) based, have been adminis-
trated in the first- and second-line settings, respectively.
Among the groups of interest, median OSs (mOSs) were
15 months (95% CI, 10–16 months), 13 months (95% CI,
12–14 months), and 7.5 months (95% CI, 6–10 months) for
PACC, MPCAC, and PASC, respectively (log-rank P = 0.0007)
(Fig. 1A); PACC, MPCAC, and PASC showed TTP-1 of
7 months (95% CI, 5–8 months), 6 months (95% CI, 5–10 months),
and 4 months (95% CI, 2–6 months), respectively (log-rank
P = 0.0227) (Fig. 1B). No statistically significant difference was
found among the groups of interest for TTP-2.
In Figure 2, a comparison among themOSs of all histological
subgroups has been reported both as curves and as histograms.
Pancreatic solid pseudopapillary carcinoma has a better survival
with an mOS of 16 months (95% CI, 14–23 months) than the
others. Aworse prognosis has been observed among the following
subgroups: PSCC (mOS of 7 months), carcinosarcoma (mOS of
5 months), and pancreatoblastoma (mOS of 5 months).
Survival analyses for each subgroup in relation with the differ-
ent chemotherapy regimens showed lack of statistical significance© 2018 Wolters Kluwer Health, Inc. All rights reserved.
                        Copyright © 2018 Wolters Kluwer Health, Inc. Unautho
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ing trend in mOS of PACC patients (Fig. 3). In fact, patients treated
with FP plus oxaliplatin seem to have a better survival respect to
patients who did not receive it (Fig. 3A). Moreover, patients treated
with gemcitabine alone had aworse survival than the others (Fig. 3B).
Clinical data of each patient according to different histotypes
are summarized in Table 2 and analyzed below.Pancreatic Adenosquamous Carcinoma
The following first-line chemotherapy regimenswere used in
the 16 evaluated patients who were evaluated: gemcitabine plus
nab-paclitaxel (3 patients), gemcitabine plus oxaliplatin (GEMOX)
(3 patients), gemcitabine plus 5-fluorouracil (5-FU) (4 patients),
gemcitabine alone (3 patients), 5-FU plus oxaliplatin and irinotecan
(FOLFIRINOX) (1 patient), 5-FU plus leucovorin plus oxaliplatin
(FOLFOX) (1 patient), and 5-FU plus cisplatin (1 patient). Six pa-
tients received one of the following second-line treatments: 5-FU
plus leucovorin plus irinotecan (FOLFIRI) (3 patients), capecita-
bine (1 patient), and FOLFOX (2 patients).
In the first-line setting, only 1 patient (in 3) treated with
gemcitabine achieved a partial response (PR), whereas 9 patients
and 6 patients achieved a stable disease (SD) and a progression
of disease (PD), respectively. Two patients showed a prolongedwww.pancreasjournal.com 3
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TABLE 2. Treatment, Response, and TTP for First- and Second-Line Treatment With OS for Each Patient of Our Collection
N. pts First Line Response TTP-1, mo Second Line Response 2 TTP-2, mo OS, mo
Acinar cell carcinoma
1 Gemcitabine + nab-paclitaxel SD 8 Gemcitabine + capecitabine SD 6 20
2 Gemcitabine + nab-paclitaxel PD 3 8
3 Gemcitabine + nab-paclitaxel PD 1 4
4 Gemcitabine + oxaliplatin PR 11 Capecitabine SD 11 29
5 Gemciatbine + oxaliplatin SD 6 De Gramont SD 5 12
6 Gemciatbine + oxaliplatin PD 2 Nab-paclitaxel PD 2 9
7 Gemciatbine + 5-FU PR 7 Taxol PD 1 13
8 Gemciatbine + 5-FU SD 14 17
9 PEXG SD 10 12
10 PEXG SD 7 Gemcitabine + oxaliplatin SD 4 15
11 PEXG SD 6 8
12 PEXG SD 5 8
13 PEXG SD 5 7
14 Gemcitabine SD 11 18
15 Gemcitabine SD 9 De Gramont PD 1 15
16 Gemcitabine SD 8 10
17 Gemcitabine SD 4 Capecitabine PD 2 8
18 Gemcitabine PD 2 FOLFIRINOX PR 8 16
19 5-FU + cisplatin SD 10 16
20 5-FU + cisplatin SD 5 FP-oxaliplatin SD 12 20
21 FP-oxaliplatin SD 7 Epirubicin + cisplatin SD 6 16
22 FP-oxaliplatin SD 7 Gemcitabine SD 6 20
23 Epirubicin + cisplatin SD 18 21
Adenosquamous carcinoma
1 Gemcitabine + nab-paclitaxel SD 6 7
2 Gemcitabine + nab-paclitaxel SD 3 6
3 Gemcitabine + nab-paclitaxel PD 3 4
4 Gemciatbine + oxaliplatin SD 6 FOLFIRI PR 6 17
5 Gemciatbine + oxaliplatin SD 5 FOLFIRI PD 1 8
6 Gemciatbine + oxaliplatin PD 2 6
7 Gemcitabine + 5-FU SD 4 Capecitabine PD 2 8
8 Gemciatbine + 5-FU SD 4 7
9 Gemciatbine + 5-FU PD 2 FOLFOX SD 3 7
10 Gemciatbine + 5-FU PD 2 4
11 Gemcitabine PR 5 FOLFOX SD 7 14
12 Gemcitabine SD 10 11
13 Gemcitabine PD 2 FOLFIRI SD 6 9
14 FOLFIRINOX SD 9 12
15 FP-oxaliplatin SD 6 10
16 5-FU + cisplatin PD 2 3
Carcinoma with medullary histology
1 GEMOX 8 8 De Gramont PD 2 13
Carcinosarcoma
1 Adriamycin-ifosfamide SD 8 10
2 Gemcitabine + nab-paclitaxel PD 3 Epirubicin PD 1 5
3 Gemcitabine + 5-FU PD 2 Capecitabine PD 2 5
4 Gemcitabine + 5-FU PD 2 3
5 Gemciatbine + nab-paclitaxel PD 1 5
Clear cell carcinoma
1 Gemcitabine + nab-paclitaxel PR 11 Capecitabine + oxaliplatin PD 3 15
2 Gemcitabine + oxaliplatin PR 6 Capecitabine SD 4 14
(Continued on next page)
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TABLE 2. (Continued)
N. pts First Line Response TTP-1, mo Second Line Response 2 TTP-2, mo OS, mo
Mucinous cystoadenocarcinoma
1 Gemcitaibine + nab-paclitaxel PD 2 FOLFOX PR 9 13
2 Gemcitaibine + cisplatin SD 10 FOLFIRI SD 6 19
3 Gemcitaibe + cisplatin SD 7 FOLFIRI SD 5 15
4 Gemcitaibine + cisplatin PR 21 Nab-paclitaxel SD 8 37
5 Gemciatbibne + oxaliplatin SD 6 FOLFIRI PD 2 10
6 Gemcitaibine + erlotinib PR 11 Capecitabine PD 2 14
7 Gemcitabine + erlotinib PD 4 Capecitabine + oxaliplatin PD 2 12
8 PEXG SD 5 7
9 Gemcitabine SD 16 19
10 Gemcitabine SD 6 Gemcitabine + cisplatin PD 3 12
11 Gemcitabibine + 5-FU PD 2 Capecitabine PD 2 7
12 Gemcitabine + 5-FU SD 11 14
13 FOLFIRINOX SD 5 Gemcitabine + nab-paclitaxel SD 3 9
14 FOLFIRINOX SD 7 Gemcitabine PD 3 12
15 FOLFIRINOX SD 6 Gemcitabine + nab-paclitaxel PD 3 14
Osteoclast-like carcinoma
1 Trabectedin PD 2 PEXG SD 5 8
2 Gemcitabine SD 6 8
Pancreatoblastoma
1 PEXG PD 4 5
Signet ring cell carcinoma
1 Gemcitabine + 5-FU SD 5 8
2 Gemcitabine SD 12 Capecitabine PD 1 17
3 Gemcitabine SD 13 14
4 FOLFIRINOX PD 1 1
Solid pseudopapillary carcinoma
1 Gemcitabine + oxaliplatin SD 5 Gemcitabine + 5-FU SD 9 17
2 Gemcitabine + oxaliplatin PD 2 Gemcitabine + 5-FU SD 8 14
3 Gemcitabine + 5-FU SD 5 Capecitabine SD 6 15
4 Gemcitabine SD 22 23
Squamous cell carcinoma
1 Gemcitabine + cisplatin SD 5 Gemcitabine PD 1 7
2 Gemcitabine PD 3 4
3 Gemcitabine SD 7 8
Undifferentiated (anaplastic) carcinoma
1 Gemcitabine + nab-paclitaxel SD 6 8
2 Gemcitaibine + nab-paclitaxel PR 7 14
3 Gemcitabine + 5-FU PD 1 FOLFIRI PR 24 25
GEMCAP indicates gemcitabine plus capecitabine.
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                 SD with TTP-1 of 10 and 9 months for gemcitabine and
FOLFIRINOX, respectively. Within the group of patients who
underwent a second-line chemotherapy, we observed 1 patient with
PR with an OS of 17 months, 3 with SD, and 2 with PD. In this set-
ting, FOLFIRI was associatedwith 1 PR (TTP-2 of 6months) and 1
SD (TTP-2 of 7 months). Five patients showed an OS of 10 months
or longer. Four of them received an oxaliplatin-based regimen.Other Exocrine Ductal Pancreatic
Adenocarcinoma Variants
Two of the 4 patients affected by SRCCPs received
gemcitabine alone as first-line therapy. Both of them showed an
SD with 12 and 13 months of TTP-1 and 17 and 14 months of
OS, respectively.We observed the lack of activity of FOLFIRINOX© 2018 Wolters Kluwer Health, Inc. All rights reserved.
                        Copyright © 2018 Wolters Kluwer Health, Inc. Unautho
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citabine as second-line therapy resulted ineffective in 1 patient.
Of 3 patients with PSCC, 2 received gemcitabine with 1 SD
(7 and 8 months of TTP-1 and OS, respectively) and 1 PD (3 and
4 months of TTP-1 and OS, respectively). The third patient treated
with gemcitabine plus cisplatin achieved an SD (5 and 7 months
of TTP-1 and OS, respectively). No second-line therapies were
performed in these patients.
The combination of gemcitabine plus nab-paclitaxelwas admin-
istered in 2 patients affected by undifferentiated (anaplastic) carci-
noma, with 1 PR (7 and 14months of TTP-1 andOS, respectively) and
1 SD (6 and 8 months of TTP-1 and OS, respectively). The combina-
tion of gemcitabine plus 5-FUwas ineffective in the third patient who
showed a PR to FOLFIRI as second-line chemotherapy with a PR and
a TTP-2 of 24 months. This last patient achieved an OS of 25 months.www.pancreasjournal.com 5
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                  Two patients suffering from osteoclast giant-like cell carcinoma
received trabectedin and gemcitabine as first-line chemotherapy with
a PD (TTP-1 of 2 months) and an SD (TTP-1 of 6 months), re-
spectively. The former was treated with combination of cisplatin,
epirubicin, capecitabine, and gemcitabine (PEXG) as second-line
treatment with an SD and 5 months of TTP-2. Both of them
achieved an OS of 8 months.
Very Rare Ductal Pancreatic Adenocarcinoma Variants
Among patients with very rare variants of the PDAC, 2 of
them were affected by clear cell carcinoma. Both achieved a PR
after gemcitabine plus nab-paclitaxel and GEMOX, respectively.
Time from first-line chemotherapy to tumor progression were 11
and 6 months, respectively. They received capecitabine plus
oxaliplatin (XELOX) and capecitabine as second-line chemother-
apy, with 1 PD and 1 SD, respectively. Overall survivals were 15
and 14 months, respectively.
The only patient with pancreatic carcinoma with medullary
histology was treated with GEMOX and de Gramont as first- and
second-line treatment with an SD (TTP-1 of 8 months) and PD
(TTP-2 of 2 months), respectively. Overall survival was 13 months.
Mucinous Cystadenocarcinoma of the Pancreas
We assessed 15 patients affected by MPCAC. They received
the following first-line regimens: gemcitabine plus nab-paclitaxel
(1 patient), gemcitabine plus cisplatin (3 patients), GEMOX (1 pa-
tient), gemcitabine plus erlotinib (2 patients), cisplatin plus epirubicin
plus capecitabine plus gemcitabine (PEXG) (1 patient), gemcitabine
(2 patients), gemcitabine plus 5-FU (2 patients), and FOLFIRINOX
(3 patients). Ten patients achieved an SD, and 3 patients achieved
a PD. Only 2 patients achieved a PR with gemcitabine plus erloti-
nib (TTP-1 of 11 months) and with gemcitabine plus cisplatin
(TTP-1 of 21 months), respectively. This latter received a
second-line therapy with nab-paclitaxel with an SD and TTP-2
and OS of 8 and 37 months, respectively. Four patients achieved
an OS equal to or greater than 15 months. Three of them received
gemcitabine plus cisplatin as first-line therapy.
Twelve patients received one of the following second-line treat-
ments: FOLFOX (1 patient), FOLFIRI (3 patients), nab-paclitaxel
(1 patient), capecitabine (2 patients), XELOX (1 patient), gemcitabine
plus cisplatin (1 patient), gemcitabine plus nab-paclitaxel (2 pa-
tients), and gemcitabine (1 patient). One patient treated with
FOLFOX achieved a PR with 9 months of TTP-2. Four patients
achieved an SD (1 of them treated with nab-paclitaxel reaching
8 months of TTP-2), and 7 achieved a PD.
Pancreatic Acinar Cell Carcinoma
The following first-line chemotherapy regimenswere used in
the 23 evaluable patients: gemcitabine plus nab-paclitaxel (3 pa-
tients), GEMOX (3 patients), gemcitabine plus 5-FU (2 patients),
PEXG (5 patients), gemcitabine (5 patients), 5-FU plus cisplatin
(2 patients), FP plus oxaliplatin (2 patients), and epirubicin plus
cisplatin (1 patient). Two cases of PRwere obtained withGEMOX
and gemcitabine plus 5-FU (TTP-1: 11 and 7 months), respec-
tively. We observed 17 SD and 4 PD cases. A patient treated with
the combination of epirubicin plus cisplatin reached a prolonged
SD with 18 months of TTP-1.
Twelve patients received one of the following second-line
treatments: gemcitabine plus capecitabine (1 patient), capecitabine
(2 patients), de Gramont (2 patients), nab-paclitaxel (1 patient),
paclitaxel (1 patient), GEMOX (1 patient), FOLFIRINOX (1 patient),
FOLFOX (1 patient), epirubicin plus cisplatin (1 patient), and
gemcitabine (1 patient). Only 1 patient treated with FOLFIRINOX
achieved a PR. Two patients underwent a long SD with a TTP-2 of6 www.pancreasjournal.com
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survival was equal to or greater than 20 months in 5 patients.
Solid Pseudopapillary NeoplasmsWithHigh-Grade
Malignant Transformation
Two patients were treated with GEMOX, achieving 1 SD and
1 PD with TTP-1 of 5 and 2 months, respectively. Both of them
received gemcitabine plus 5-FU as second line, achieving an SD
with TTP-1 of 9 and 8 months, respectively. One patient received
a first-line treatment with gemcitabine plus 5-FU followed by cap-
ecitabine after progression, with an SD for both treatments and an
OS of 15 months. It was interesting to observe that a patient
treated with gemcitabine alone achieved a long-duration SD with
TTP-1 and OS of 22 and 23 months, respectively.
Pancreatoblastoma
The only patient with pancreatoblastoma reported in this
study received PEXG as first-line therapy, achieving an SD, with
4 and 5 months of TTP-1 and OS, respectively.
Pancreatic Carcinosarcoma
Five patients were treated with gemcitabine plus nab-paclitaxel
(2 patients), gemcitabine plus 5-FU (2 patients), and adriamycin plus
ifosfamide (1 patient), with only 1 SD obtained with the latter che-
motherapy regimen. Only 2 patients received a second-line treat-
ment with epirubicin and capecitabine, respectively. Both of
them showed a PD.
DISCUSSION
Systemic chemotherapeutic regimens for advanced rare his-
tological types of pancreatic cancer are not established. So far,
in most of the cases, clinicians have chosen antineoplastic drugs
according to result of clinical trials considering PDAC patients.
In the past, gemcitabine alone10 or in combination with a platinum
salt11,12 or an FP13,14 represented the most used regimens. In the
last few years, FOLFIRINOX,15 PEXG,16 and nab-paclitaxel plus
gemcitabine17 became the criterion standard in the first-line set-
ting of fit PDAC patients.To the best of our knowledge, this is
the first multicentric retrospective analysis of systemic treatments
performed in patients with advanced pancreatic exocrine pheno-
types different from PDAC.
Pancreatic Adenosquamous Carcinoma
Pancreatic adenosquamous carcinoma represents 1% to 4%
of all exocrine pancreatic cancers. It is characterized by a bad
prognosis,18–20 with an OS of 4 months reported in a Surveillance,
Epidemiology, and End Results database.21 Despite several data
regarding clinical and pathological features,22,23 very little informa-
tion is available regarding systemic therapeutic options. In particu-
lar, the role of cisplatin or oxaliplatin in addition to gemcitabine
has been supported by a study performed in an adjuvant setting,
which reported a significantly longer median survival associated
with this combination compared with gemcitabine or 5-FU alone.24
In the metastatic setting, a retrospective analysis by Imaoka et al25
considered 22 patients with advanced PASC who received
gemcitabine alone (16 patients), gemcitabine plus S1 (1 patient),
5-FU plus concurrent radiotherapy (1 patient), or best supportive
care (3 patients), with no information regarding efficacy and
activity of these treatments. De Souza and Saif26 reported the
result obtained in 2 patients with advanced disease treated with
gemcitabine in combination with cisplatin and oxaliplatin. The
first patient achieved an SD with a TTP-1 of 8 months; the sec-
ond achieved a PR with a TTP-1 of 6 months. Capecitabine© 2018 Wolters Kluwer Health, Inc. All rights reserved.
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                 represented the second-line treatment for both of them with
TTP-2 of 18 and 24 weeks, respectively.26 In our study, we ob-
served the clinical activity of oxaliplatin-based regimens in 3
untreated patients.
Pancreatic Squamous Cell Carcinoma
Pancreatic squamous cell carcinoma represents approxi-
mately 0.2% of all pancreatic exocrine malignancies.27 Only sin-
gle case reports are available in literature that consider the
treatment of patients with advanced disease. The combination of
5-FU plus cisplatin was associated with on OS from 6 to
15 months.28–30 De Souza and Saif31 administered the combina-
tion of gemcitabine plus cisplatin with an SD and a progression-
free survival (PFS) of 6 months. This patient received 5-FU and
leucovorin as second-line therapy with an SD and a PFS of
3 months. In another patient, the combination of gemcitabine plus
oxaliplatin was associated with 6 and 9 months of PFS and OS,
respectively.32 Al-Shehri et al33 evaluated the combination of
gemcitabine plus carboplatin who underwent a PD with an OS
of 4 months. Our data are consistent with the above literature in
terms of OS obtained with gemcitabine alone or in combination
with cisplatin.
Signet Ring Cell Carcinoma of the Pancreas
Very few case reports are available in literature with no data
regarding the treatment in advantage stages.34–37 In our series,
gemcitabine alone was associated with a good activity and effi-
cacy profile. On the contrary, we observed the lack of activity of
FOLFIRINOX in 1 patient with a TTP-1 of only 1 month.
Undifferentiated (Anaplastic) Carcinoma
This histotype has been referred to with several names: pleo-
morphic carcinoma, pleomorphic giant cell carcinoma, round cell
carcinoma, spindle cell carcinoma, and mainly undifferentiated
(anaplastic) carcinoma.38 This tumor represents approximately
2% to 7% of all pancreatic carcinomas.39,40 The North American
National Cancer Data Base reported an mOS of 11.1 months based
on the consideration of all stages.41 Even for this histotype, clini-
cal,42 pathological, and biomolecular43 features have been exhaus-
tively studied. Because of its aggressive behavior and rapid
recurrence, benefits of systemic therapies have not yet been demon-
strated.44 Wong et al.45 administered GEMOX in combination with
radiofrequency ablation of stable liver metastases and obtained an
SD with an OS of 15 months. Interestingly, Wakatsuki et al46 used
a chemosensitivity testing with ATP assay using fresh specimens of
pleiomorphic pancreatic cancer from a patient with metastatic dis-
ease with the aim to predict the activity of anticancer agents in this
tumor. The assay revealed a high chemosensitivity to paclitaxel.
The patient was treated with this drug achieving a complete re-
sponse (CR) after 2 cycles and a disease-free survival of
23 months.46 Ungaro et al47 reported the lack of activity of cis-
platin plus gemcitabine in a patient who received FOLFIRI in
combination with high-intensity focused ultrasound with a PR.
Shinagare et al48 described the history of a patient treated with
FOLFIRINOXwho showed a PR even if OSwas only of 5months
because of the deterioration of the clinical status. Interestingly,
even if in only 2 cases, for the first time we reported a favorable
activity profile of the combination of gemcitabine plus nab-
paclitaxel in this subset of patients.
Osteoclast Giant-like Cell Carcinoma
This rare histotype shows similar histological features to
pleomorphic giant cell carcinoma from which it differs because© 2018 Wolters Kluwer Health, Inc. All rights reserved.
                        Copyright © 2018 Wolters Kluwer Health, Inc. Unautho
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It accounts for less than 1% of all pancreatic malignancies.50 The
North American National Cancer Data Base reported an mOS of
48 months including all stages,41 even if mOS for patients with
advanced disease was less than 1 year with few exceptions.51
The combination of gemcitabine plus erlotinib was associated
with a rapid PD.52 Yoshioka et al53 treated an elderly patient
with metastatic disease with gemcitabine alone with a CR after
5 months. Time from first-line chemotherapy to tumor progres-
sion and OS were 12 and 19 months, respectively. Similarly,
Chiarelli et al54 described the history of a patient treated with
gemcitabine alone with an SD and 6 and 10 months of TTP-1
and OS, respectively. Jones et al55 obtained a PR after neoad-
juvant FOLFIRINOX. We confirmed the clinical activity of
gemcitabine in our patient.
Pancreatic Clear Cell Carcinoma
Very few data are available regarding the incidence and sur-
vival of these patients.56–58 Gemcitabine alone and mitomycin
plus 5-FU combination had no activity in a patient with metastatic
disease.59,60 For the first time, we reported a promising activity
profile of gemcitabine-based chemotherapy regimens in 2 patients
who showed OSs of 15 and 14 months, respectively. Furthermore,
similar positive results have been obtained with the combination
of gemcitabine plus nab-paclitaxel, in a patient for whom TTP-1
and OS were 11 and 15 months, respectively.
Pancreatic Carcinoma With Medullary Histology
Overall 2- and 5-year survival rates of this tumor are approx-
imately 29% and 13%, respectively.61 No data are available re-
garding chemotherapy treatment. We reported the unique case of
a patient treated with GEMOX as first-line chemotherapy, who
achieved an SD with a TTP-1 of 8 months.
Mucinous Cystadenocarcinoma of the Pancreas
The incidence of this malignancy ranges from 2.4% to 14%
of all pancreatic malignancies.62,63 The Surveillance, Epidemiol-
ogy, and End Results database approximately estimated that the
mOS calculated in patients with advanced diseasewas 4months.64
Few indications are available in advanced setting. Obayashi
et al65 described the history of a patient with liver metastases
treatedwith 16 courses of GEMOXwho achieved a CR on hepatic
metastases followed by the resection of the primary mass. Simi-
larly, a patient with peritoneal and ovarian metastases was treated
with 12 cycles of GEMOX with a PR, which allowed the surgical
resection of primary and metastatic lesions.66 A patient with
metastatic disease treated with gemcitabine alone achieved a
marked shrinkage of the metastatic lesions.67 Werner et al68
treated 5 patients with gemcitabine, achieving PR in 1, SD in
1, and PD in 3 patients, with an mOS of 11 months. On the con-
trary, gemcitabine-based combinations were associated with a
short OS in 2 other patients.69,70 In our series, we confirmed
the activity of the combination of gemcitabine plus cisplatin.
Furthermore, 3 patients had FOLFIRINOX achieving an SD.
The combination of gemcitabine plus nab-paclitaxel was ineffec-
tive in both first- and second-line settings in our 3 patients.
Pancreatic Acinar Cell Carcinoma
Pancreatic acinar cell carcinoma is another rare pancreatic
exocrine tumor (1%–2% of all cases)4 with an mOS of 17 to
19 months in the advanced stages.71,72 For what concerns sys-
temic treatments, a retrospective study considering 18 patients at
Memorial Sloan Kettering Cancer Center reported only 2 patientswww.pancreasjournal.com 7
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TABLE 3. Analysis of Treatment, Response, and TTP for First- and Second-Line Treatment With OS in Literature Reports
Ref. First Line Response
TTP-1,
mo Second Line Response 2
TTP-2,
mo OS, mo
Adenosquamous cell carcinoma
26 Gemcitabine + cisplatin SD 8 Capecitabine SD 4 NR
26 Gemcitabine + oxaliplatin PR 6 Capecitabine SD 6 NR
Squamous cell carcinoma
31 Gemcitabine + cisplatin SD 6 De Gramont SD 3 NR
32 Gemcitabine + oxaliplatin SD 6 9
33 Gemcitabine + carboplatin PD NR 4
Undifferentiated (anaplastic) carcinoma
45 GEMOX + RF (liver metastases) SD NR 15
46 Paclitaxel CR 23
47 Cisplatin + gemcitabine PD 1 FOLFIRI + high-intensity
focused ultrasound
PR NR NR
48 FOLFIRINOX PR NR 5
Osteoclast giant-like cell carcinoma
52 Gemcitabine plus erlotinib SD 8 10
53 Gemcitabine CR 12 19
54 Gemcitabine SD 6 10
55 FOLFIRINOX PR NR NR
Mucinous cystoadenocarcinoma
65 GEMOX CR 22
66 GEMOX PR NR NR
67 Gemcitabine PR NR NR
68 Gemcitabine-based treatment
(5 patients)
1 PR, 1 SD, and
3 PD
11 (Median)
69 Gemcitabine-based CT SD NR 6
70 Gemcitabine-based CT PD NR 3
Acinar cell carcinoma
73 FOLFIRI PR NR 7 (Not for disease)
73 Cytarabine, cisplatin, and caffeine PR 6 NR
73 5-FU SD NR NR
72 Gemcitabine + irinotecan SD 25 30
72 Gemcitabine + irinotecan SD 8 GEMOX PR 5 35
72 Gemcitabine PD 2 Cisplatin + irinotecan PR 25 34
72 Gemcitabine + capecitabine SD 9 FOLFIRI PD 3 21
72 GTX PR 11 GEMOX NR NR 44
72 GTX SD 7 11
72 Gemcitabine + cisplatin PR NR GEMOX PD 3 68+
74 Gemcitabine PD 2 S1 PR NR 13
74 Gemcitabine SD 6 S1 SD 10
75 Capecitabine PR 12 FOLFOX PR 6 43+
75 FOLFOX PR/SD 12 FOLFIRI SD 3 26
75 Gemcitabine + erlotinib PD 6 FOLFOX SD 22 68
75 Gemcitabine SD 7 Pemetrexed PD NR 34
75 FOLFIRINOX SD 5 Gemcitabine +
nab-palitaxel
PD NR 9
75 GEMOX PD 3 Capecitabine SD 56 150+
75 Gemcitabine + erlotinib PD 2 Capecitabine PD 2 6
75 FOLFIRINOX PR 8 Gemcitabine +
nab-palitaxel
PD 3 19
75 Gemcitabine PD 1 4
75 Gemcitabine + erlotinib PD 2 FOLFIRINOX PR 9 25
75 FOLFIRINOX PR 14 15+
(Continued on next page)
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TABLE 3. (Continued)
Ref. First Line Response
TTP-1,
mo Second Line Response 2
TTP-2,
mo OS, mo
75 GEMOX PR 6 (Shift to)
gemcitabine + erlotinib
PR 13 45
76 S1 PR NR 24
77 S1 SD 73+
78 FOLFIRINOX SD 9 NR
79 FOLFIRINOX CR (liver met)
SD (primary)
NR NR
Solid pseudopapillary carcinoma
89 Tamoxifen SD NR 22
90 5-FU + doxorubicin + mitomycin-C PD NR NR
91 Cisplatin + 5-FU PR NR NR
92 Cisplatin + ifosfamide + etoposide
+ vincristine
PR NR NR
93 VP-16, cisplatin, cyclophosphamide,
doxorubicin, and vincristine
PR NR 24
94 5-FU + concomitant RT PD NR Gemcitabine PR NR NR
Pancreatoblastoma
100 Cisplatin + doxorubicin Mixed
radiographic
response
3 Docetaxel + gemcitabine PD NR 5
101 Streptozocin, doxorubicin, and
gemcitabine + chemoembolization
with radiolabeled somatostatin
CR 51 NR
96 Cisplatin + doxorubicin NR NR <10
Pancreatic carcinosarcoma
106 Gemcitabine SD/PD NR NR
CT indicates chemotherapy; GTX, gemcitabine, capecitabine, and docetaxel; NR, not reported; Ref, reference.
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                 with PR obtained with FOLFIRI and the combination of cytarabine
plus cisplatin and caffeine, respectively.73 Six patients with PRwere
reported at the same institution in another retrospective study with
the following regimens: GEMOX (2 patients), gemcitabine-
docetaxel-capecitabine (1 patient), cisplatin plus irinotecan (1
patient), cisplatin plus gemcitabine (1 patient), and gemcitabine plus
erlotinib (1 patient). One patient received GEMOX as second-line
therapy with a PR and a TTP-2 of 6 months.72 No data supported
the activity of gemcitabine alone as first-line therapy in this subset
of patients.74,75 One patient treated with GEMOX (8 cycles)
achieved a PR. Subsequently, the treatment was switched to
gemcitabine plus erlotinib with a PR (13 months).75 Seki et al74
reported 2 Asian cases of advanced PACC treated with S1 after
the failure of first-line treatment with gemcitabine achieving PR
in 1 and SD in 1 with 13 and 10months of OS, respectively. In an-
other patient, S1 alone was associated with a PR and an OS of
24 months.76 Sumiyoshi et al77 described a patient with advanced
PACC treated with S1 after distal pancreatectomy with evidence
of peritoneal involvement who was alive 73 months after the
diagnosis. FOLFOX or FOLFIRINOX obtained PR in 4 and pro-
longed SD in 2. In particular, the use of FOLFIRINOX as first-
line therapy led to an SD with 3 months of PFS and 2 with PR
with a PFS of 6 and 14 months, respectively. One patient treated
with this regimen in second-line therapy achieved a PR with a
PFS of 9 months.75 Similarly, Callata-Carhuapoma et al78 re-
ported the history of a patient who achieved a prolonged SD
(TTP of 9 months) after FOLFIRINOX. Also, a 63-year-old
patient treated with the same regimen achieved a CR of he-
patic lesions and a PR of pancreatic mass.79 Pfrommer et al80© 2018 Wolters Kluwer Health, Inc. All rights reserved.
                        Copyright © 2018 Wolters Kluwer Health, Inc. Unautho
                This paper can be cited using the date of access and the unreported the unique case of a young man with an advanced
mixed PACC and PDAC who showed an exceptional response
to FOLFIRINOX. After a perioperative administration of cisplatin
and doxorubicin (PLADO regimen), he underwent a Whipple
duodenopancreatectomy with simultaneous wedge resection of
liver metastases. At the recurrence, a first-line chemotherapy with
2 cycles of ifosfamide, carboplatin, and etoposide (ICE regimen)
was performed with a PR. Soon after, he received 2 liver trans-
plantations (right hemiliver) from both his brother and a cadaveric
liver graft after 10 days. Five months later, multiple new lung me-
tastases were detected. So far, hewas administered FOLFIRINOX
regimen with a complete metabolic response and a partial radio-
logical response of all lung lesions. Because of the excellent re-
sponse to FOLFIRINOX, the authors decided to consolidate this
result with tandem high-dose chemotherapy using carboplatin,
etoposide, and paclitaxel as conditioning regimen followed by au-
tologous stem cell transplantation. Six months later, FOLFIRINOX
was started again because of a new lung progression with a PR. At
the time of publication, approximately 45 months after diagnosis,
the patient was still alive. Disappointing results have been ob-
tained with the combination of gemcitabine plus nab-paclitaxel
in 2 cases.76
Very few data are available in the second-line setting. Yoo
et al81 reported 8 cases who received gemcitabine alone (4 pa-
tients) or FOLFOX (4 patients), respectively. No responses were
obtained in the first group. Patients treated with FOLFOX pre-
sented 3 PR and 1 SD case with a median PFS of 6.5 months.
Lastly, some authors considered the administration of so-
matostatin analogs in the care and prevention of fat necrosiswww.pancreasjournal.com 9
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                  nodule, an event that has been reported in these patients with the
resolution of fat panniculitis associated with PACC.82–84
In our series, we confirmed the activity of FOLFIRINOX
that was administered as second-line therapy in 1 patient who
showed a PR. A patient treated with the combination of epirubicin
plus cisplatin reached a TTP-1 of 18 months. Intriguingly,
5 patients receiving a platinum salt achieved anOS equal to or lon-
ger than 20 months. Moreover, 12 patients had an OS equal to or
longer than the mOS of our cases (15 months); 10 of them were
treated with a platinum compound in the first- or second-line set-
tings, or both. Contrasting data emerged from the use of
gemcitabine plus nab-paclitaxel. On one side, 1 of 3 patients
treated with this combination reached SD with 8 and 20 months
of TTP-1 and OS, respectively. On the contrary, 2 of them experi-
enced a rapid PD with OSs of 8 and 4 months, respectively.
In summary, gemcitabine alone does not have a role in PACC
patients, as has been demonstrated in our results (Fig. 3B).
According to our findings (Fig. 3A) and literature data, the
combination of an FP with a platinum salt is associated with
a favorable activity and efficacy profile. As for the newest
chemotherapy combination regimen, FOLFIRINOX could represent
a valuable therapeutic option.
Solid Pseudopapillary NeoplasmsWithHigh-Grade
Malignant Transformation
This tumor, which represents 2% to 3% of all pancreatic ma-
lignancies,85 is characterized by a low malignant potential, due to
its benign morphology and nonfrequent metastasis.86,87 As a con-
sequence, it displays a good prognosis, with an mOS of 8 years.88
So far, malignant transformation in solid pseudopapillary neo-
plasms is exceedingly rare, althoughwhen it occurs neoplasms be-
came highly aggressive.
Intriguingly, Sclafani et al89 described the history of a patient
with metastatic disease with positive estrogen receptors treated
with tamoxifen with an OS of 22 months. A combination of
5-FU, doxorubicin, and mitomycin-C was not effective in a case
report.90 On the contrary, the combination of cisplatin plus 5-FU
in a locally advanced tumor was associated with a PR, allowing
the surgical resection of the tumor.91 A combination of cisplatin,
ifosfamide, etoposide, and vincristine was associated with a PR
of liver metastases, which allowed a radiofrequency-combined
surgical resection of a primary tumor.92 Tipton et al93 reported a
PR associated with an OS of 2 years in a patient who received a
combination of VP-16, cisplatin, cyclophosphamide, doxorubi-
cin, and vincristine. A locally advanced tumor was treated with
5-FU plus concomitant radiation, achieving clinical progression.
He received gemcitabine alone with a PR, which allowed
pancreatoduodenectomy.94 The lowaggressive biology of the tumor
is confirmed by the history of a patient who underwent several lines
of treatment: gemcitabine alone (6 cycles), gemcitabine plus
irinotecan (3 cycles), oxaliplatin plus irinotecan and capecitabine
(8 cycles), gemcitabine plus capecitabine (6 cycles), and weekly
5-FU. Finally, in the last 2 years until publication of the data, the pa-
tient received capecitabine alone.95 All patients considered in our
study received gemcitabine alone or in combinationwith oxaliplatin
or 5-FU with only SD.
Pancreatoblastoma
Pancreatoblastoma typically mainly occurs in the pediatric
population, with approximately only 40 cases described in
adults.96,97 Prognosis in this small group of patients is dismal,
with an mOS of 5 months in the advanced stages.98 In children,
PLADO regimen represents the criterion standard in the first-
line setting.99 Very limited information regarding adult patients10 www.pancreasjournal.com
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received a first-line therapy with cisplatin plus doxorubicin, with
a mixed radiographic response and a TTP of 3 months. After pro-
gression, the administration of docetaxel plus gemcitabine resulted
ineffective. The combination of capecitabine plus oxaliplatin third-
line therapywas associated to a TTPof 4months.100 Salman et al101
reported the history of a patient with metastatic disease who re-
ceived a first-line therapy with streptozocin, doxorubicin, and
gemcitabine in conjunction with chemoembolization using
radiolabeled somatostatin, with a TTP of 51 months. Zouros
et al96 unsuccessfully treated a recurrent pancreatoblastoma
with PLADO regimen with an OS after recurrence of less than
10 months. We reported a very short TTP-1 and OS concerning
the first patients treated with PEXG as first-line therapy.
Pancreatic Carcinosarcoma
Pancreatic carcinosarcoma is a very rare histotype of pancre-
atic cancer with approximately only 20 cases reported in the liter-
ature.102,103 Gelos et al104 reviewed 7 cases, with an OS after
surgery of 6 months. Jia et al103 considered 19 cases and calcu-
lated anmOS of 9months using the Kaplan-Meier method includ-
ing cases of all stages. Herein, we reported one of the more
significant series of advanced pancreatic carcinosarcoma, whose
mOS was 5 months. Despite several available data reporting path-
ological105 and radiological102 features, only few authors reported
data concerning systemic therapies. Gemcitabine alone resulted
ineffective in 2 advanced cases.103,106
Among 4 of our 5 patients, 2 were treated with gemcitabine
plus nab-paclitaxel, and 2 were treated with gemcitabine plus
FU. All of them showed a PD with an OS equal to or shorter than
5 months. Our fifth patient was treated with adriamycin plus
ifosfamide with a TTP-1 of 8 months and an OS of 10 months.
CONCLUSIONS
The very low incidence of these malignancies and the lack of
knowledge concerning their biological features represent the main
obstacles in the definition of a chemotherapy regimen that can be
recommended in these patients. In this retrospective analysis of
chemotherapeutic approaches in advanced rare exocrine pancre-
atic histotype, we tried to answer to the clinical needs in treatments
of these patients with locally advanced or metastatic disease. Nev-
ertheless, the heterogeneity of the reported data in combination
with the revision of the literature (Table 3) allowed us to
suggest, in some cases, possible therapeutic options.
Because of the lack of the possibility to perform clinical trials
in patients affected by rare pancreatic malignancies, we believe
that only their molecular classification could help clinicians in
their therapeutic choice.
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